303 related articles for article (PubMed ID: 25511502)
1. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?
Kiper AK; Rinné S; Rolfes C; Ramírez D; Seebohm G; Netter MF; González W; Decher N
Pflugers Arch; 2015 May; 467(5):1081-90. PubMed ID: 25511502
[TBL] [Abstract][Full Text] [Related]
2. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.
Decher N; Kumar P; Gonzalez T; Pirard B; Sanguinetti MC
Mol Pharmacol; 2006 Oct; 70(4):1204-11. PubMed ID: 16835355
[TBL] [Abstract][Full Text] [Related]
3. Identification of the A293 (AVE1231) Binding Site in the Cardiac Two-Pore-Domain Potassium Channel TASK-1: a Common Low Affinity Antiarrhythmic Drug Binding Site.
Wiedmann F; Kiper AK; Bedoya M; Ratte A; Rinné S; Kraft M; Waibel M; Anad P; Wenzel W; González W; Katus HA; Decher N; Schmidt C
Cell Physiol Biochem; 2019; 52(5):1223-1235. PubMed ID: 31001961
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
[TBL] [Abstract][Full Text] [Related]
6. Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode.
Strutz-Seebohm N; Gutcher I; Decher N; Steinmeyer K; Lang F; Seebohm G
Cell Physiol Biochem; 2007; 20(6):791-800. PubMed ID: 17982261
[TBL] [Abstract][Full Text] [Related]
7. TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes.
Rinné S; Kiper AK; Schlichthörl G; Dittmann S; Netter MF; Limberg SH; Silbernagel N; Zuzarte M; Moosdorf R; Wulf H; Schulze-Bahr E; Rolfes C; Decher N
J Mol Cell Cardiol; 2015 Apr; 81():71-80. PubMed ID: 25655935
[TBL] [Abstract][Full Text] [Related]
8. Atrial-selective K
Ravens U
Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
[TBL] [Abstract][Full Text] [Related]
9. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
Peukert S; Brendel J; Pirard B; Brüggemann A; Below P; Kleemann HW; Hemmerle H; Schmidt W
J Med Chem; 2003 Feb; 46(4):486-98. PubMed ID: 12570371
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1.
Du YM; Zhang XX; Tu DN; Zhao N; Liu YJ; Xiao H; Sanguinetti MC; Zou A; Liao YH
J Mol Cell Cardiol; 2010 Jun; 48(6):1111-20. PubMed ID: 20184887
[TBL] [Abstract][Full Text] [Related]
11. Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K
Wiedmann F; Schulte JS; Gomes B; Zafeiriou MP; Ratte A; Rathjens F; Fehrmann E; Scholz B; Voigt N; Müller FU; Thomas D; Katus HA; Schmidt C
Basic Res Cardiol; 2018 Jun; 113(4):27. PubMed ID: 29881975
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
Bachmann A; Gutcher I; Kopp K; Brendel J; Bosch RF; Busch AE; Gögelein H
Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):472-8. PubMed ID: 11692231
[TBL] [Abstract][Full Text] [Related]
13. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.
Baczko I; Liknes D; Yang W; Hamming KC; Searle G; Jaeger K; Husti Z; Juhasz V; Klausz G; Pap R; Saghy L; Varro A; Dolinsky V; Wang S; Rauniyar V; Hall D; Dyck JR; Light PE
Br J Pharmacol; 2014 Jan; 171(1):92-106. PubMed ID: 24102184
[TBL] [Abstract][Full Text] [Related]
15. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.
Tamargo J; Caballero R; Gómez R; Delpón E
Expert Opin Investig Drugs; 2009 Apr; 18(4):399-416. PubMed ID: 19335273
[TBL] [Abstract][Full Text] [Related]
16. Kv1.5 blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology.
Bilodeau MT; Trotter BW
Curr Top Med Chem; 2009; 9(5):436-51. PubMed ID: 19519460
[TBL] [Abstract][Full Text] [Related]
17. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
18. Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.
Guo X; Chen W; Sun H; You Q
Curr Top Med Chem; 2016; 16(16):1843-54. PubMed ID: 26975505
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
